Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jaguar Health Inc JAGX

Healthcare
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing... see more

Recent & Breaking News (NDAQ:JAGX)

Jaguar Health Announces Launch of Mytesi Telehealth Program

Accesswire May 11, 2022

Jaguar Health Provides Company Updates and Reports 2022 First Quarter Financials

Accesswire May 10, 2022

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Accesswire May 6, 2022

UPDATED RELEASE: Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates

Accesswire May 5, 2022

Jaguar Health to Host Investor Webcast Tuesday, May 10th at 8:30 AM Eastern Time Regarding Q1 2022 Financials & Corporate Updates

Accesswire May 5, 2022

Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea (EID) in Dogs

Accesswire May 3, 2022

Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Accesswire April 27, 2022

Jaguar Health to Present at the NobleCon18 Investor Conference on April 21, 2022

Accesswire April 20, 2022

Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)

Accesswire April 15, 2022

Jaguar Animal Health to Host Dinner & Tableside Discussion for U.S. Veterinary Oncologists About Chemotherapy-Induced Diarrhea (CID) in Dogs on April 12th, the Final Day of the Veterinary Cancer Society (VCS) Mid-Year Conference in Puerto Vallarta, Mexico

Accesswire April 6, 2022

Jaguar Health Announces Appointment of Pravin Chaturvedi, Ph.D., as Chief Scientific Officer

Accesswire April 5, 2022

Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets

Accesswire March 31, 2022

Jaguar Health Shares Replay Link for March 14, 2022, Investor Webcast

Accesswire March 14, 2022

Jaguar Health Provides Company Updates and Reports 2021 Financials

Accesswire March 11, 2022

Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates

Accesswire March 7, 2022

Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas

Accesswire March 1, 2022

Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs

Accesswire February 16, 2022

Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency

Accesswire February 15, 2022

Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs

Accesswire February 10, 2022

Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD)

Accesswire February 1, 2022